Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00888173 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

NETWORK

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Mixed Adenocarcinoma
Endometrial Mucinous Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Squamous Cell Carcinoma
Endometrial Transitional Cell Carcinoma
Endometrial Undifferentiated Carcinoma
Recurrent Uterine Corpus Carcinoma

Interventions

DRUG: Brivanib Alaninate
OTHER: Laboratory Biomarker Analysis

Sponsor

Gynecologic Oncology Group

Collaborators

[object Object]